Earlier, AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.53, $0.17 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.66 billion versus the consensus estimate of $6.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

Earnings